Frederick M. Miesowicz

Frederick Miesowicz joined Argos Therapeutics in 2003. Prior to this, Dr. Miesowicz was the Vice President of U.S. Operations for Gamida-Cell, a stem cell company. He was Senior Vice President and General Manager of Hybridon Specialty Products. He served as Vice President and General Manager of Cellcor, a subsidiary of Cytogen, Inc., from 1995 to 1998, where he directed all operations related to Cellcor’s cellular immunotherapy programs. He also served as Senior Vice President of Scientific Affairs at Cellcor from 1992 to 1995. Dr. Miesowicz has an extensive background in cellular therapies and medical devices. Prior to joining Cellcor, he managed the U.S. and European SteriCell Division of Terumo Medical Corporation after it was acquired from DuPont, and was with E.I. DuPont de Nemours & Company for over 14 years managing both immunotherapy and immunodiagnostic R&D groups. Dr. Miesowicz holds a B.S. degree in Chemistry from Siena College and received a Ph.D. in Chemistry from Harvard University.